No Data
Evercore ISI's initial price target for BioNTech is $100
Greenhui, May 15 | Evercore ISI Group: Covered BioNTech for the first time, giving it a “in sync with the market” rating. The target price is $100.
BioNTech (BNTX.US) was first covered by Evercore ISI Group, which gave the market a simultaneous rating, with a target price of $100.00.
BioNTech (BNTX.US) was first covered by Evercore ISI Group, which gave the market a simultaneous rating, with a target price of $100.00.
Evercore ISI Group Initiates Coverage On BioNTech With In-Line Rating, Announces Price Target of $100
Evercore ISI Group analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ:BNTX) with a In-Line rating and announces Price Target of $100.
We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade
Analysts Conflicted on These Healthcare Names: BioNTech SE (BNTX), Xenon (XENE) and BioLife Solutions (BLFS)